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Abstract
Magnetic resonance (MR) imaging of the liver is an 
important tool for the detection and characterization 
of focal liver lesions and for assessment of diffuse 
liver disease, having several intrinsic characteristics, 
represented by high soft tissue contrast, avoidance 
of ionizing radiation or iodinated contrast media, and 
more recently, by application of several functional 
imaging techniques (i.e. , diffusion-weighted sequences, 
hepatobiliary contrast agents, perfusion imaging, 
magnetic resonance (MR)-elastography, and radiomics 
analysis). MR functional imaging techniques are 
extensively used both in routine practice and in the field 
of clinical and pre-clinical research because, through 
a qualitative rather than quantitative approach, they 
can offer valuable information about tumor tissue and 
tissue architecture, cellular biomarkers related to the 
hepatocellular functions, or tissue vascularization profiles 
related to tumor and tissue biology. This kind of approach 
offers in vivo  physiological parameters, capable of 
evaluating physiological and pathological modifications 
of tissues, by the analysis of quantitative data that could 
be used in tumor detection, characterization, treatment 
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selection, and follow-up, in addition to those obtained 
from standard morphological imaging. In this review we 
provide an overview of recent advanced techniques in MR 
for the diagnosis and staging of hepatocellular carcinoma, 
and their role in the assessment of response treatment 
evaluation.
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Core tip: Magnetic resonance (MR) of the liver is an 
important diagnostic option for detection and cha-
racterization of focal liver lesions. To date, beside the 
standard morphological sequences, new functional 
imaging tools (i.e. , diffusion-weighted sequences, 
hepatobiliary contrast agents, perfusion imaging, MR-
elastography, or radiomics analysis) have been introduced 
in clinical practice. The aim of functional imaging is to 
provide in vivo  quantitative complementary functional 
data related to the tissue or tumor modifications, offering 
useful comprehensive information about the biology, 
behavior, and prognosis of hepatocellular carcinoma 
lesions. This functional approach may help clinicians 
correctly manage cirrhotic patients, also after therapeutic 
treatment.
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INTRODUCTION
Liver cancer is the fifth most frequently diagnosed 
malignancy among men and the ninth among women. 
Recently, it has risen from the third to the second cause 
of death from cancer, accounting for nearly 746000 
deaths in 2012. In some regions, like Eastern and 
South-Eastern Asia, mortality almost equals incidence 
with an overall ratio of 0.95[1]. The most common 
histological subtype of liver cancer is hepatocellular 
carcinoma (HCC), representing more than 90% of 
cases. The incidence of HCC increases with advanced 
age, reaching, at least in developed countries, a peak 
at 70 years[2]. In up to 90% of cases, HCC occurs in the 
setting of liver cirrhosis and overall, one-third of cirrhotic 
patients will develop HCC during their lifetimes[3].
The primary risk factor for HCC is still represented by 
chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) 
infection[4], with a prevalence of virus B infection in 
Eastern countries and a prevalence of virus C infection 
in Western countries. Other causes of cirrhosis comprise 
alcohol abuse, non-alcoholic fatty liver disease (NAFLD), 
and less frequent disorders such as hemochromatosis. 
All etiologies could lead to cirrhosis and may be 
complicated by tumor formation, but the risk is higher 
in patients with hepatitis infection. In the coming 
years, the diffusion of new antiviral agents for HCV[5], 
vaccination and therapy for HBV[6], and prevention 
campaigns are expected to reduce the burden of chronic 
viral liver disease and its complications, including 
HCC[7]. On the other hand, the widespread epidemic of 
obesity is expected to induce a significant increase in 
the incidence of NAFLD and its complications, such as 
NASH, cirrhosis, and HCC[8,9].
Liver cirrhosis is a common underlying condition 
associated with hepatocarcinogenesis. Cirrhosis develops 
after a long period of chronic liver disease, when the risk 
of HCC is still low. The nodules that could be potentially 
found in a cirrhotic liver comprise: Small and large 
regenerative nodule (RN), low-grade dysplastic nodule 
(LGDN), high-grade dysplastic nodule (HGDN), early 
HCC, well-differentiated HCC, and moderately-poorly 
differentiated HCC. Hepatocarcinogenesis is a multistep 
event during which cell density increases, Kuppfer cells 
decrease, nodules enlarge, and hemodynamics change. 
In the initial phase, normal arterial supply decreases 
but portal perfusion is still present. Later, intranodular 
arterial vascularity increases due to the appearance 
of unpaired arteries (capillarization) while portal blood 
supplies progressively decrease[10]. Simultaneously, 
organic anionic transporting polypeptide (OATP), 
transporters of bile salts, gradually decrease. OATP 
expression levels are high in RNs and LGDNs and 
lower in many HGDNs, early HCCs, and progressed 
HCCs. The hemodynamic changes are well depicted 
during dynamic multidetector computed tomography 
(MDCT) and magnetic resonance imaging (MRI), and 
both European and American guidelines have endorsed 
this technique for the diagnosis of HCC > 1 cm, based 
on the typical hallmarks of hypervascularity in arterial 
phase with wash-out in portal phase, thereby avoiding 
liver biopsy[11,12].
However, there remains a high rate of false 
negative, ranging from 25%-30%, in particular for 
nodules < 2 cm[13,14], which actually are the most often 
encountered focal liver lesions, thanks to the widespread 
of surveillance programs. In these small nodules, 
hemodynamic changes of hepatocarcinogenesis are in 
an early stage, since neoangiogenesis is incomplete and 
they are still mainly filled by portal vessels, in contrast 
to progressed HCC. MRI in part overcomes these limits. 
It has been recently demonstrated that this diagnostic 
technique has a higher diagnostic performance over 
computed tomography (CT) in the detection of high-
risk nodules[15]. This is due to its high contrast resolution 
and to its multiparametric characteristics. In fact, it is 
known that hyperintensity on T2 weighted sequences 
and restricted diffusion in diffuse weighted images 
(DWI) are features of malignancy[16]. Moreover the 
recent introduction of hepatospecific MRI contrast agent 
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gadolinium-ethoxybenzyl-dieth-ylenetriamine pentaacetic 
acid (Gd-EOB-DTPA, Primovist®; Bayer Schering Pharma, 
Berlin, Germany), which gives information not only 
on vascular changes but also on hepatocyte function, 
raises the sensitivity for the detection of early HCC 
to 91%-93%[17]. Based on this feature, Kim BR and 
colleagues[16] demonstrated that readers had significantly 
higher detection sensitivity for early HCCs with MRI than 
with multidetector CT (78.6% vs 52.4%, P = 0.001; 
71.4% vs 50.0%, P = 0.011; and 73.8% vs 50.0%, P 
= 0.001, respectively), as shown by 30 more LI-RADS 
category 4 early HCCs identified at MRI. 
The correct characterization of all nodules possibly 
encountered in a cirrhotic liver is of paramount impor-
tance because they are managed completely differently. 
In fact, while regenerative and dysplastic nodules 
deserve a strict follow-up, HCC should be treated with 
the more suitable therapeutic option, according its 
stage. This is clearly defined by the Barcelona Clinic 
Liver Cancer (BCLC) staging system, adopted in all 
Western countries and endorsed by both American and 
European guidelines.
In this context, beside traditional radiological 
techniques, new functional imaging tools have been 
introduced in clinical practice in order to provide not 
only morphological information but also functional data 
information. Functional magnetic resonance imaging 
encompasses a wide range of advanced techniques 
capable of evaluating physiological and pathological 
modifications of tissues, by the analysis of quantitative 
data, in addition to those obtained from standard 
morphological imaging. These techniques may include 
diffusion-weighted sequences, hepatobiliary contrast 
agents, perfusion imaging, MR-elastography, and more 
recently radiomics analysis. In particular, perfusion 
imaging (related to vascular profile) and diffusion 
imaging (related to cellular profile) (Figure 1) techniques 
have been extensively studied during various steps 
of HCC evolution, from initial assessment of vascular 
modifications in cirrhotic liver, through its progression in 
tumor lesion, and finally to its follow-up after treatment. 
Hence, in this review, we provide an overview of recent 
advances and techniques in MR studies for the diagnosis 
and the staging of HCC.
CONTRAST MEDIA: EXTRACELLULAR 
AND HEPATOBILIARY AGENTS
Gadolinium is a paramagnetic ion that shortens T1 
relaxation time in tissues and, therefore, produces an 
increase in signal intensity[18]. Based on bio-distribution, 
there are three categories of gadolinium-based contrast 
agents: extracellular fluid agents (ECFAs), blood pool 
agents (BPCAs), and targeted and organ-specific contrast 
agents, such as hepatocyte-specific contrast agents 
(HCAs). ECFAs and HCAs are the most commonly used 
in liver imaging. ECFAs consist of gadolinium chelated 
to an organic compound, such as DTPA[19]. They are 
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Figure 1  Schematic comparison between diffusion weighted images (on the left) and perfusion maps (on the right) showing the meaning from the 
pathophysiological point of view of the two different functional magnetic resonance techniques. The diffusion offers qualitative information strictly related to 
tissue cellularity, while perfusion sequences offer qualitative information about tissue vascularization.
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(‘‘the one-third rule’’)[25]. Indeed, the intranodular 
hemodynamic changes during carcinogenesis start 
with an arterial hypovascularity with portal perfusion 
still present, followed by a decrease of both arterial 
and portal blood supply, then followed by an increase 
in arterial vascularity to isovascular, and, finally, to a 
hypervascular pattern[12].
On the other hand, several recent studies demon-
strated that the expression of OATP diminishes during 
hepatocarcinogenesis[26]. Moreover, OATP 8 expression 
level decreases prior to complete neoangiogenesis, 
with elevation of arterial flow and reduction of portal 
venous flow[27]. Thanks to their lipophilic characteristics, 
HCAs, after the intravascular/interstitial distribution, are 
taken up by functioning hepatocytes, metabolized, and 
excreted into the bile through the OATP 8: Consequently, 
nodules with low or no OATP expression (the majority of 
HCC, many early HCCs, and some high-grade dysplastic 
nodules) do not uptake HCAs and appear hypointense 
in the hepatobiliary phase (HBP) (Figure 2). A recent 
meta-analysis has shown that the impact of HBP on a 
per-lesion sensitivity is significant, in particular the use 
of Gd-EOB-DTPA allowed a sensitivity of 87% vs 74% 
(P = 0.03) the one without HBP[28]. Based on these 
considerations, the current contrast agents applied in the 
study of the liver are the gadobenate dimeglumine (Gd-
BOPTA/Dimeg, MultiHance®, Bracco, Milan, Italy), which 
is a chelate of the paramagnetic gadolinium ion salified 
with two molecules of meglumine, and gadolinium 
ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-
EOB-DTPA, Primovist®, Bayer Schering Pharma, Berlin, 
Germany), which is a highly water-soluble contrast 
agent with an ethobenzyl group attached to gadolinium 
diethylenetriamine pentaacetic acid[29]. The approved 
dose of Gd-BOPTA for hepatic imaging is 0.05 mmol/kg 
(0.1 mL/kg of a 0.5 mol/L solution)[30], and it should be 
administered undiluted followed by a normal saline “flush” 
of 20 to 50 mL. Hepatic uptake represents 2%-4% of 
the injected dose for Gd-BOPTA, and the HBP is typically 
performed between 45 and 120 min after injection and is 
necessary in order to achieve sufficient enhancement.
The approved dose of Gd-EOB-DTPA is 0.025 mmol/kg, 
which is considered the minimum effective dose for 
the detection of liver lesions in the hepatobiliary phase. 
further divided in standard relaxivity macrocyclic agents, 
standard relaxivity linear agents, and high relativity 
linear agents (Table 1). The details regarding the 
advantages and disadvantages of each contrast category 
is beyond the scope of this article, but in general, there 
is little clinical difference[20]. The standard dose is 0.1 
mmol/kg typically injected intravenously at a rate of 
2 mL/s followed by a normal saline “flush” of 20 to 50 
mL. After the injection, ECFAs are rapidly cleared from 
the intravascular space through the capillaries into the 
extracellular space. They are mainly eliminated by renal 
excretion and have imaging dynamics comparable 
to the extracellular iodinated contrast media used in 
CT. However, MRI is more sensitive to the effects of 
gadolinium than CT is to the effects of iodine, because 
gadolinium has an amplification effect due to the 
number of adjacent water protons relaxed by a single 
gadolinium atom[19,21]. In summary, ECFAs enter into 
the liver through the hepatic artery and portal vein and 
are freely redistributed into the interstitial space; they 
demonstrate vascular perfusion by distributing and allow 
the evaluation of liver lesions based on assessment 
of vascularity. The combination of arterial phase 
hyperenhancement followed by washout appearance 
in the portal venous and/or delayed phase is the key 
diagnostic feature of HCC[11,12] (Figure 2). 
The pathophysiologic basis for arterial phase 
hyperenhancement in HCC is related to the increasing 
of the intranodular arterial supply during hepato-
carcinogenesis[22]. The mechanisms underlying washout 
appearance in HCC depend on a range of factors: 
early venous drainage of contrast material from the 
tumor, progressive enhancement of background liver, 
reduced intranodular portal venous blood supply, 
tumor hypercellularity with corresponding reduction 
in extracellular volume, and intrinsic hypoattenuation/
hypointensity[23]. In cirrhotic patients, this enhancement 
pattern has approximately 100% specificity for lesions 
larger than 2 cm and approximately 90% specificity 
for those of 1-2 cm[24]. However, the main limitation 
with ECFAs for diagnosis and staging HCCs is low 
per-lesion sensitivity, because an atypical vascular 
behavior is quite common in small (< 2 cm) nodules 
and approximately one-third of these are malignant 
Table 1  Gadolinium-based magnetic resonance imaging contrast agent
Contrast agent Category Relaxivity Structure Concentration 
(mmol/mL)
Reccomended dosage 
(mmol/kg)
Gadoterate-meglumine ECFAs Standard macrocyclic 0.5 0.1
Gadobutrol ECFAs Standard macrocyclic 1.0 0.1
Gadoteridol ECFAs Standard macrocyclic 0.5 0.1
Gadopentetate- dimeglumine ECFAs Standard Linear 0.5 0.1
Gadoversetamide ECFAs Standard Linear 0.5 0.1
Gadodiamide ECFAs Standard Linear 0.5 0.1
Gadofosfaset-trisodium BPCAs High Linear 0.25 0.03
Gadobenate- dimeglumine HCAs High Linear 0.5 0.1
Gadoxetate-disodium HCAs High Linear 0.25 0.025
ECFAs: Extracellular fluid agents; BPCAs: Blood pool agents; HCAs: Hepatocyte-specific contrast agents.
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The modalities of gadoxetic acid administration were 
addressed in the ESGAR consensus statement[31] (flow-
rate of 1-2 mL/s followed by a 20 mL saline flush at 
1-2 mL/s using a bolus triggering technique). Hepatic 
uptake represents 50% for Gd-EOB-DTPA, and the 
HBP reaches its maximum intensity approximately 
20 min after injection with gadoxetate disodium and 
persists for several hours[32]. The clinical use of liver-
specific contrast agents allows the radiologist to obtain 
morphologic and vascular-related information, although 
an overlap between delayed phase and hepatocyte phase 
have to be considered during dynamic evaluation[33]. 
A recent meta-analysis[34] reported that in trials of 
MRI that directly compared test performance using 
different contrast agents, use of HCAs was associated 
with higher sensitivity than ECAs (difference of 13%), 
with no difference in specificity. The difference was 
somewhat greater for HCC lesions smaller than 2 cm 
(difference of 15%). These finding were stressed by 
the ESGAR consensus[31], who stated that a Gd-EOB-
DTPA MR examination should be performed in order 
to characterize an undetermined focal liver lesion of 
10 mm or larger in the cirrhotic liver. In summary, 
HCAs allow a comprehensive non-invasive imaging 
assessment of the liver parenchyma, intrahepatic lesions 
depiction or characterization, hepatic vasculature, and 
the biliary tree in a single examination. They have 
several advantages in the evaluation of the cirrhotic 
liver including: (1) Higher sensitivity for the diagnosis of 
HCC, in particular for lesions smaller than 2 cm[34]; (2) 
improved characterization of arterially enhancing lesions 
without definite washout on subsequent imaging[35]; (3) 
the possibility to differentiate arterially enhancing lesion 
vs pseudolesions[36]; and (4) detection of lesions with 
decreased uptake evidenced only in the HBP that are 
likely to be precancerous or borderline lesion[37]. 
PERFUSION IMAGING 
Perfusion MRI in the assessment of HCC focuses on 
the detection and characterization of lesions[38-40], 
the evaluation of response to therapy[38,41-44], and 
determination of prognosis[44,45] (Table 2). 
The basis of dynamic contrast-enhanced (DCE)-
perfusion MR imaging is the acquisition of multiple image 
sets, every few seconds, through the tumor or as much 
of the organ as possible, after gadolinium injection. 
The rate and pattern of contrast enhancement reflects 
Lesion                                                                                                 Sequences
Unenhanced T1            Arterial             Portal venous              Delayed              Hepatobiliary                DWI                       T2
HCC classic
HCC green
HCC 
hypovascular
HCC classic
HCC green
HCC 
hypovascular
EC
A
H
BA
Isointense lesion               Hyperintense lesion                Hypointense lesion              Slightly hyperintense lesion
Figure 2  Schematic representation showing dynamic contrast enhanced sequences, diffusion weighted images, and T2-weighted features in typical, 
green, and hypovascular hepatocellular carcinoma, comparing information from extracellular contrast agent and hepatobiliary contrast agent. ECA: 
Extracellular contrast agent; HBA: Hepatobiliary contrast agent; DWI: Diffusion weighted images.
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the time evolution of the contrast agent within the 
tissue, which occurs as a result of the microcirculatory 
pathophysiological changes. Perfusion MRI could extend 
the currently used qualitative assessment applied for the 
differential diagnosis of lesions, by applying quantitative 
metrics to describe their vascular behaviour. 
The main purpose of MRI perfusion is the quanti-
fication of vascular characteristics of HCC, because the 
growth and progression of histological malignancy of 
HCC are associated with new blood vessels formation[46] 
(angiogenesis). Moreover, the targets of anti-angiogenic 
drugs, recently used for HCC treatment, are represented 
by these new blood vessels and, therefore, the perfusion, 
as a functional imaging technique, may be suitable for 
evaluating patients treated with these agents[47-50].
Dynamic contrast-enhanced magnetic resonance 
imaging (DCE-MRI) provides non-invasive imaging 
biomarkers that can measure changes in tumor 
blood flow, vascular permeability, and interstitial and 
intravascular volumes[40,43,47] and can predict the survival 
outcome in patients with HCC[51-53]. Generally, DCE-MRI 
consists of acquisition of T1-weighted MR images before, 
during, and after intravenous injection of a gadolinium-
based contrast agent[40]. The contrast agent extravasates 
at level of tumor tissue, from intravascular to the 
extravascular extracellular space (EES) with increased 
T1-w signal[43,54,55]. This extravasation to EES in the 
tumor tissue depends on vessel leakiness (permeability) 
and blood flow (perfusion), and so the signal measured 
with DCE-MRI could be sensitive to alterations in 
vascular permeability, EES, and blood flow[43,54].
DCE-MRI signals can be quantified using a semi-
quantitative (model free) or quantitative (model 
based) analysis[56]. Both analysis methods have several 
parameters related with tumor angiogenesis[54,57] and can 
give different information on liver and tumor perfusion[56]. 
Briefly, with the semi-quantitative analysis, all perfusion 
parameters are extracted directly from time-signal 
intensity (SI) curves [e.g., AUC, maximum SI or peak 
enhancement ratio, wash-in slope, mean transit time 
(MTT)], derived from different dynamic contrastographic 
sequences. Although widely used, semi-quantitative 
analysis is highly affected by the acquisition systems and 
comparison and quantification of these parameters can 
be difficult[56,57] because the true concentration of contrast 
agent in the tissues is not estimated (Figure 3). 
Quantitative analysis depends on fitting the time 
SI curves with the changes in concentration of the 
contrast agent using pharmacokinetic techniques using 
several kinetics models based on different physiological 
assumptions made[56]. These kinetics models can be 
bi-compartmental models (taking into account vessels 
and EES) or mono-compartmental (taking into account 
the vascular space because of the typical architecture 
of the liver)[56], with a double or single input system 
(arterial and portal or arterial alone), conventional 
compartment (CC) models vs distributed parameters 
(DP) models[54,56].
Several parameters extracted with quantitative 
analysis are related to the influx of contrast agent from 
the intravascular space to the EES (K trans) and its 
reverse (Kep), the volume fraction of EES (Ve), which 
is an indirect expression of the cellular density of the 
tissue[43,54,56]. 
In comparison to the semi-quantitative analysis, 
these parameters are more time consuming because 
they generate parametric maps through a pixel-by-pixel 
curve fitting process. Although the histogram analysis 
and the heterogeneity of these parametric maps are 
more computationally demanding, they may also 
provide additional information[43,56]. Moreover, numerous 
pharmacokinetic models have been proposed by Tofts 
Table 2  Magnetic resonance imaging perfusion with dynamic contrast-enhanced magnetic resonance imaging in the assessment of 
hepatocellular carcinoma, focus on diagnosis, characterization, response to therapy, and prognosis
Ref. Year Magnet (Tesla) Contrast agent Parameters
Diagnosis and characterization
   Taouli et al[38] 2013 1.5 T Gadobenate-dimeglumine and gadopentetate-
dimeglumine
AF, VF, ART, DV, MTT
   Chen et al[39] 2017 3 T GD-EOB-DTPA Ktrans, Kep, iAUC, max-Ktrans
   Jajamovich et al[40] 2016 3 T Gadobenate-dimeglumine ART, K trans, ve, kep, τ
   Abdullah et al[61] 2008 1.5 T Gadoterate-dimeglumine HPI, MTT, DV, TF, AF, PF
Response to therapy
   Ippolito et al[41] 2016 1.5 T GD-EOB-DTPA ME, MRE, RAE, RE, RLE, RVE, TTP
   Taouli et al[38] 2013 1.5 T Gadobenate-dimeglumine and Gadopentetate-
dimeglumine
AF, VF, ART, DV, MTT
   Chen et al[45] 2016 1.5 T Gadodiamide Peak, Slope, AUC, Ktrans, Kep, Ve
Prognosis
   Chen et al[45] 2016 1.5 T Gadodiamide Peak, Slope, AUC, Ktrans, Kep, Ve
   Chen et al[45] 2016 1.5 T Gadodiamide ART, AF, PF, TF, MTT, DV, PEAK, SLOPE, AUC
ART: Arterial fraction; K trans: Contrast agent transfer rate constant from plasma to extravascular extracellular space; VE: Extravascular extracellular 
volume fraction; Kep: Contrast agent intravasation rate constant; τ: Mean intracellular water molecule lifetime; ME: Maximum enhancement; MRE: 
Maximum relative enhancement; RAE: Relative arterial enhancement; RE: Relative enhancement; RLE: Relative late enhancement; RVE: Relative venous 
enhancement; TTP: Time to peak; HPI: Hepatic perfusion index; MTT: Mean transit time; DV: Distribution volume; TF: Total blood flow; AF: Arterial blood 
flow;  PF: Portal blood flow; AUC: Area under the gadolinium distribution-time curve.
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et al[58], Brix et al[59], and Larsson et al[60], using a single 
arterial input function[43]. Because HCC receives major 
blood supply from hepatic neo-arteries and often arise 
from a cirrhotic liver, the single input model (considering 
only the arterial input) and the dual compartment model 
(because of the alteration in the EES) are frequently 
both used in the literature[54,56].
However, because of numerous DCE-MRI–related 
limitations, parameters derived from these pharma-
cokinetic models may lack sufficient precision for clinical 
application[38], and there is no consensus regarding the 
pharmacokinetic model that should be used to quantify 
HCC perfusion parameters, even if some studies 
demonstrated that some pharmacokinetic models can 
be equivalent in the results[40]. 
All these possibilities and differences in the field of 
DCE-MRI led to literature studies with different results. 
In general, two recent studies demonstrated 
that HCC had significantly higher peak, slope, AUC, 
arterial fraction, and arterial flow but lower portal 
flow, distribution volume, and MTT than the liver[45]. 
HCCs with high peak are correlated to a longer overall 
survival (OS) in comparison with HCC with low peak[45] 
before systemic therapy. Secondly, high peak reduction 
assessed early (1 wk) after systemic therapy can be 
related to OS[44]. 
DCE-MRI semi-quantitative parameters (relative 
arterial, venous, and late enhancement; maximum 
enhancement; maximum relative enhancement, and 
time to peak) potentially can be used also to differentiate 
residual viable tumor tissue and effective treated lesions 
after TACE or RFA[41]. Some of them, in a multivariate 
analysis, seemed also to predict the response to 
radiotherapy RT[42].
Some groups found that with DCE-MRI it is possible 
to quantify the perfusion in the liver and HCC with an 
increased arterial flow and decreased portal venous flow 
in HCC compared with cirrhotic liver, with significant 
differences in the degree of arterial versus portal venous 
blood flow in treated and untreated HCCs[38].
Perfusion parameters could be correlated to the 
grading differentiation of HCC, but in most of the cases, 
there were no significant differences in perfusions and 
grade of HCC differentiation, with the exception of 
the arterial fraction (ART)[40]. The ART parameter is a 
value estimated each time through perfusion equations 
A B C D
E F G H
I J K L
Figure 3  Gd-EOB-DTPA enhanced magnetic resonance images of a 67-year-old male patient with large hepatocellular carcinoma lesion in the right liver 
lobe. Panels A-B: T1-weighted sequences “in and out of phase” demonstrate a heterogeneous mass slightly hypointense without a signal drop in “out of phase” 
sequence. Panels C-D: T2-weighted image without and with fat saturation demonstrates a slightly hyperintense mass with a central, homogeneous hyperintense area, 
as per necrosis. Panels E-H: Dynamic contrast-enhanced images delineate the typical contrast behavior of hepatocellular carcinoma (HCC): Hyperenhancement 
during the arterial phase (F) followed by wash-out in portal and delayed phase (G-H). In the hepatobiliary phase image 20 min after Gd-EOB-DTPA injection the 
nodule appears highly hypointense compared with the surrounding enhanced liver (panel I). Panel J: On the diffusion weighted image, HCC lesion is hyperintense due 
to the restriction of water diffusion. Panel K-L: Perfusion images derived from semiquantitative analysis (relative arterial enhancement and maximum enhancement) 
the HCC is characterized by high vascularity intensity signals, shown as hot-spots signals. 
Ippolito D et al . Advances in magnetic resonance liver
2420 June 21, 2018|Volume 24|Issue 23|WJG|www.wjgnet.com
obtained from the addition of the two input inflow 
(arterial and portal) into one[40]. Moreover, it has been 
suggested that ART can be used to assess response to 
local regional therapy in HCC[38,40,61].
In a recent study from Chen et al[39], the max-
Ktrans seemed to correlate with tumor grades (rho = 
-0.382, P = 0.028). The Ktrans, Kep, and iAUC of high-
grades HCC were significantly lower than that of low-
grades HCC (P = 0.001, 0.031, 0.003, respectively), 
but there was no statistically significant differences for 
Ve between high grade and low grade HCC (P > 0.05)[39].
These results suggest that DCE-MRI can be useful 
as a non-invasive marker of HCC angiogenesis, but new 
equipment and sequences and models are still under 
investigation. New equipment will be applied in the near 
future to quantify the perfusion of HCC, as a biomarker 
of degree of malignancy, prognosis, and response to 
therapy[38-40].
DIFFUSION WEIGHTED IMAGING
DWI is a functional MRI sequence that allow the 
characterization of biological tissues based on the diffusion 
properties of water molecules, providing information 
about tissue cellularity and about the integrity of cellular 
membranes[2]. In fact, in high cellular tissue, the higher 
density of hydrophobic cellular membranes reduces the 
“apparent” diffusion of water protons[62], thus the water 
diffusion can be considered relatively “restricted”. More 
simply the “diffusion restriction” refers to a tumor signal 
intensity that is higher than the surrounding parenchyma 
(the liver for example) on high b-value DW MR images, 
and, to date, DW-imaging represents an integral part of 
the routine MR protocol for liver disease (Figure 4). 
In 2010, Taouli et al[63] defined DW MR imaging, an 
attractive technique, which was reaching a potential 
for clinical use in the abdomen, particularly in the liver. 
Less than a decade later, all the potential uses of DWI 
are greatly shown, and diffusion can be considered a 
useful tool for the diagnosis of focal liver lesions, with 
better results than T2-weighted images[64] especially 
in HCC[65]. There are various reasons why: DWI adds 
useful qualitative and quantitative information to 
standard sequences; it has a short acquisition time and 
can be easily included to existing protocols; and it does 
not need the use of contrast materials[66,67].
Although several DW imaging sequences can be 
applied to evaluate the liver, the single shot spin-echo 
(SE) echo-planar technique is the most frequently 
used in combination with fat suppression. Recent 
studies[68] compared free breathing (FB) vs respiratory 
triggered (RT) DWI for detecting HCC, using a 3 T 
scanner, a 32-channel torso-cardiac phased-array coil, 
and dual-source parallel radiofrequency excitation 
and transmission technology. They concluded that FB-
DWI provided better image quality and showed higher 
detectability of HCCs in patients with chronic liver 
disease compared to RT-DWI, without significantly 
reducing the SNR of the normal liver parenchyma or 
the lesion-to-non lesion CNR. DW imaging should not 
be considered a stand-alone sequence, but should be 
integrated in MR protocols: The combination of Gd-EOB-
DTPA and DWI could allow the assessment of the three 
main processes in the hepatic multistep carcinogenesis 
(vascular changes, hepatocyte change, and tissue 
diffusivity). A recent meta-analysis showed that the 
combination of gadoxetic acid-enhanced MRI and 
DWI significantly improved both diagnostic accuracy 
and specificity for HCCs associated with chronic liver 
disease[69]. Several studies underline the importance 
that DWI adds to dynamic contrast-enhanced MRI, 
in characterization of small or atypically enhancing 
lesions[70,71]. In particular, Briani et al[71] demonstrated 
that the hypovascular lesions ≥ 10 mm that appeared 
hyperintense in DWI are associated with progression 
to hypervascular HCC. DWI can not only indicate 
the morphological characteristics of a lesion with a 
qualitative assessment, but with apparent diffusion 
coefficient (ADC) measurement, can also provide a 
quantitative index of diffusion characteristics, analyzing 
structure and tissue components. Some authors[70,72] 
suggested that a lesion-to-liver ADC ratio cut-off value 
of 0.92 may offer good sensitivity, specificity, and 
accuracy in differentiating HCC vs dysplastic nodules 
(DN). Inchingolo et al[70], furthermore, obtained higher 
values (sensitivity 90.91%, specificity 80.95%, and 
accuracy of 83.55%, when the group of LGDNs was 
compared to the group that included both HGDNs and 
HCCs, with a cut-off of 0.95. Jiang et al[73] conducted 
a retrospective analysis of the correlation between 
qualitative and quantitative DWI and HCC tumor 
grade. They found that while SI values on DWI could 
distinguish only between well-differentiated HCC and 
moderately or poorly differentiated HCC, ADC values 
could distinguish between well, moderately, and 
poorly differentiated HCC, with the consequence of 
a better pre-operative and non-invasive histological 
characterization. Further applications of DW imaging are 
still ongoing, and larger studies are needed to validate 
these results. One example is the application of DWI 
concerning the prediction of microvascular invasion 
(MVI) in HCC. MVI still remains one of the important 
prognostic factors of HCC recurrence, especially after 
surgical resection or liver transplantation[74,75]. In the 
past, other imaging characteristics have previously been 
suggested as predictors of MVI, such as tumor size, 
shape and margin, capsule, peritumoral enhancement, 
and dynamic enhancement pattern; but recently Yang 
et al[76] proposed a new integrated evaluation of T2 and 
DWI images by defining the concept of “diffusion- and 
T2-weighted imaging mismatch”. They demonstrated 
that this new “DWI/T2 mismatch” was an independent 
predictor of MVI (odds ratio 4.521, P = 0.035), with a 
high specificity (95.65%). Another potential application 
of DWI is the assessment of liver tumor response to 
novel therapy. In fact, while a change in tumor size is 
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the common effect of conventional chemotherapy, loco-
regional therapies may lead to stability of tumor size 
or even an increase in hepatic tumo. Moreover, novel 
molecular-targeted therapies may alter the morphology 
of the tumor by affecting its angiogenesis, with 
unchanged tumor size[77]. Recent studies have shown 
the possibility to differentiate viable tissue from necrosis 
on the basis of ADC cut-off values, because necrosis has 
higher ADC values[78,79]. For patients with HCC treated 
with Sorafenib, a transient decrease in tumor ADC 
value approximately 1 month after treatment has been 
reported to be suggestive of hemorrhagic necrosis; 
however, a sustained decrease in ADC at 3-mo follow-
up may indicate viable tumor or its progression[80]. ADC 
values in patients with HCC treated with transarterial 
radioembolization (TARE) have been shown to increase, 
a finding suggestive of cellular necrosis. Increased 
ADC values in such cases may be an early marker of 
treatment response before changes in tumor size are 
observed[81]. Despite the several attempts to use ADC 
values in clinical practice, reproducibility of volumetric 
quantification with diffusion-weighted imaging is not 
well established. Moreover, there are some technical 
aspects that need to be considered, like the differences 
in scanner equipments, the lack of a standardized DWI 
protocol, the low reproducibility and comparability of 
ADC measurements among different studies, and finally, 
the susceptibility of ADC maps to noise and artefacts[64]. 
MR ELASTOGRAPHY
MR elastography (MRE) is an MRI-based method for the 
quantitative assessment of liver fibrosis and increased 
stiffness. This technique is based on the application of 
mechanical waves (generated through the machine) to 
the region of interest (the liver). These waves and their 
wave-length are located in the liver through different 
elastographic sequences (the most used are gradient-
echo sequences with motion-encoding gradients) to 
obtain different set of images and maps. With two 
different reconstruction algorithms applied to this set 
of images, it is possible to obtain a final colored image, 
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Figure 4  Gd-EOB-DTPA enhanced magnetic resonance images of a 61-year-old patient with hepatocellular carcinoma nodule in the VII segment of the 
liver. Panels A-B: A single nodule slightly hypointense on the T1-weighted “in phase” sequence (A) with a signal drop in the “out of phase” sequence, as per fat 
deposition. Panels C-D: On T2-weighted image without and with fat saturation the nodule appears slightly hyperintense. Panels E-H: Dynamic contrast-enhanced 
images demonstrate the typical contrast behavior of hepatocellular carcinoma: Which appear hypervascular during the arterial phase (F) with wash-out in portal and 
delayed phase (G-H). Panel I-J: Diffusion weighted image (DWI) shows the hyperintense pattern of the lesion which appear hypointense on the relative apparent 
diffusion coefficient map (arrowhead). Previously treated lesion with transarterial chemoembolization is recognizable, in panel A-E-F-G-H, at V segment of the liver 
(arrow). No any restriction of signal intensity is evident on DWI (panel I-J).
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called “confidence map”, with different stiffness areas of 
the liver expressed with different colors that correspond 
to different in kilo-pascal values (kPa).
Different studies have demonstrated the possibility 
to use MRE for assessment of mild degree of liver 
fibrosis[82-84] and to differentiate malignant and benign 
nodules in the liver[85]. A recent study tried to understand 
if there was a correlation between HCC stiffness detected 
with MRE and HCC pathologic features[84]. Tumor stiffness 
(TS) seemed to be higher in moderate/well differentiated 
HCC in comparison to poor differentiated HCC (6.5 ± 1.2 
kPa vs 4.9 ± 1.2 kPa, P < 0.01); but at the moment, 
no correlation is found to liver parenchyma stiffness, 
vascular invasion, and tumor encapsulation[84].
Another important application of MRE regards the 
assessment to treatment response and in particular 
loco-regional treatment [90Yttrium radio-embolization 
(RE), trans-arterial chemoembolization (TACE), and 
radiofrequency ablation (RFA)][86].
In two animal studies[87,88], reduction in TS was 
associated with histologically proven central necrosis[89] 
and decreased cellular proliferation and moderate 
induction of apoptosis[88]. In a preliminary study on 
humans, MRE seems to provide early evidence of 
therapeutic response, demonstrating that treated tumors 
have significantly lower TS compared to untreated 
tumors (3.9 ± 1.8 kPa vs 6.9 ± 3.4 kPa, P = 0.006) 
and cirrhotic liver, while intra-tumoral hemorrhage is 
associated with higher TS. TS seems to relate with 
visually assessed percentage of necrosis and ER and is 
more in patients treated with RE[86]. 
MRE still has the limitation of hepatic iron overload, 
which can decrease hepatic signal intensity in gradient 
echo based MRE sequences to unacceptably low 
levels[83]. On the other hand, MRE enables qualitative 
and quantitative assessment of TF without the use of 
gadolinium chelates[86].
Despite some of the limitations of MRE, it remains 
a promising technique not only for the evaluation of 
liver fibrosis but also in the spectrum of diagnosis and 
prognosis of HCC[83,84,86].
RADIOMICS
Radiomics represents the possibility to convert 
digital medical images (CT, MR, or positron emission 
tomography images) into high-dimensional data[89]; the 
hypothesis is that biomedical images contain information 
that reflects underlying pathophysiology and that these 
relationships can be revealed via quantitative image 
analyses. MRI based radiomics signature are currently 
investigated in glioblastoma, breast, and faringeal cancer. 
Currently, there are no studies about the possibility to 
use radiomics in the assessment of HCC. Main efforts 
remain focused on some complex texture analysis, taking 
in account just few features, which represent a small and 
impaired part of radiomics data analysis.
Controversial results were obtained from different 
studies concerning the use of texture analysis in the 
assessment of HCC[90-93]. The main problems are due 
to differences in the equipment, contrast phase chosen 
for the analysis, and type of segmentation (circular ROI 
vs tumor shape ROI, slice analysis vs volumetric ROI 
analysis). Recently, two studies have been published 
on the possibility to use complex texture analysis in 
MRI to assess the malignancy of HCC (Zhou et al[94]) 
or to predict the progression of hypovascular nodules 
(detected with gadoxetate disodium acid during hepa-
tobiliary phase) into hypervascular HCC lesions[90]. In 
both studies, volumetric region of interest (VOI) was 
evaluated.
All these preliminary studies demonstrated that, 
among the different features assessed with texture 
analysis, some of them seem to perform better on a 
specific dynamic phase (arterial or hepatobiliary) and 
can give useful information. In order to differentiate low 
grade and high grade HCC[94], “mean intensity value” (a 
histogram feature) presented significantly larger values 
in low-grade HCCs than in the high-grade HCCs, and 
the values of gray-level run-length nonuniformity (GLN) 
were significantly smaller in low-grade HCCs than in 
high-grade HCCs.
Moreover, in another study, different histogram 
metrics showed the possibility to predict the progression 
of a hypovascular nodule into an HCC[90], using different 
flip angles and volumetric region of interest.
Radiomics appears to offer a nearly limitless supply 
of imaging biomarkers that could potentially aid in 
cancer detection, diagnosis, assessment of prognosis, 
prediction of response to treatment, and monitoring 
of disease status[89]. Further studies and validations 
are required for the performance of the features by 
themselves, their application according to the different 
contrast phases available during MRI sequences, and 
the different MRI equipment. 
CONCLUSION
MRI of the liver represents an important tool for the 
detection and characterization of focal liver lesions and 
for the evaluation of diffuse liver disease. The main 
advantages of MRI relies on superior soft tissue contrast, 
absence of ionizing radiation, and the possibility of 
performing functional and advanced imaging techniques. 
Unlike conventional MR imaging sequences, which are 
usually reported qualitatively based on the varying 
brightness of tissue, functional MR-imaging techniques 
offers quantitative data. Among the different functional 
MR imaging techniques, DWI, MR elastography, and 
T1-weighted DCE sequences are the most likely to 
find clinical use at present or in the near future in liver 
imaging.
MR functional imaging allows for the addition of 
qualitative and quantitative functional information to 
conventional anatomic sequences and routine clinical 
protocols, thereby offering clinicians further comprehensive 
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information about the biology, behavior, and prognosis 
about HCC lesions.
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